Abstract: ［Abstract］ ObjectiveTo investigate the effects of Sacubitril/Valsartan(Sac/Val) on cardiac function in patients with acute anterior wall ST-segment myocardial infarction(STEMI) complicated with heart failure with reduced ejection fraction(HFrEF).
〖WTHZ〗MethodsIn a prospective, randomized controlled study, 160 consecutive cases of acute anterior wall STEMI patients complicated with HFrEF after PCI were enrolled, and divided into the observation group(n=80) and the control group(n=80) using a randomized digital method. At one week after PCI, the control group received routine treatment and Valsartan(Val), while the observation group was given Sac/Val in addition to routine treatment, for a duration of 6 months treatment. Changes of plasma NT-proBNP concentration and echocardiography parameters were compared between two groups. The effect of Sac/Val in acute anterior STEMI patients with HFrEF after PCI was evaluated.
〖WTHZ〗ResultsAfter 6 months of follow-up, NT-proBNP, LVEF and WMSI were significantly improved compared with baseline in two groups(P＜0.001). However, the above indicators improved more significantly in the observation group. At the end of the follow-up, the left ventricular end systolic volume (LVESV) decreased significantly, and the major adverse cardiac events(MACE) were significantly reduced in the observation group(P＜0.05).
〖WTHZ〗ConclusionSac/Val can improve ventricular wall dyspraxia and improved left cardiac function and reduced MACE within 6 months after PCI in patients with acute anterior STEMI complicated with HFrEF.

Key words: anterior wall myocardial infarction, angioplasty, balloon, coronary, heart failure